Inactive Instrument

Press Releases Cellectis S.A. Other OTC

Equities

CMVLF

FR0010425595

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Cellectis S A : Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia	05/06	PU
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia	05/06	GL
Cellectis S A : Environmental Social & Governance Report - March 2024	04/06	PU
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024	30/05	GL
Cellectis S A : Corporate Presentation - May 2024	29/05	PU
Cellectis Reports Financial Results for First Quarter 2024	29/05	GL
Cellectis Reports Financial Results for First Quarter 2024	29/05	AQ
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024	28/05	GL
Cellectis S A : NOTICE OF MEETING COMBINED GENERAL MEETING OF SHAREHOLDERS - Form 6-K	25/05	PU
Cellectis S A : Report of the board of directors to the Combined Shareholders’ Meeting - June 28, 2024	24/05	PU
Cellectis S A : Notice of Meeting Combined General Meeting of Shareholders June 28, 2024	24/05	PU
Cellectis S A : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social	17/05	PU
Cellectis S A : Corporate Presentation - May 2024	13/05	PU
Cellectis S A : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social	07/05	PU
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca	06/05	GL
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer	03/05	GL
Cellectis S A : Announces Completion of the Additional Equity Investment by AstraZeneca	02/05	PU
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023	30/04	GL
Cellectis Presents Novel TALEN Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs	23/04	AQ
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs	23/04	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cellectis S.A. Other OTC

Equities

CMVLF

FR0010425595

Press Releases

Filters